|
|
 |
|
Viewing report
|
|
|
|
Neuroprotection - Drugs, Markets and Companies
Jain PharmaBiotech, Nov 2009, Pages: 585
This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues are similar in all these conditions and several products are used in more than one disorder. Over 500 products have been investigated for neuroprotective effects including those from the categories of free radical scavengers, anti-excitotoxic agents, apoptosis (programmed cell death) inhibitors, anti-inflammatory agents, neurotrophic factors, metal ion chelators, ion channel modulators and gene therapy. Some of the agents are old established pharmaceuticals whereas others are new biotechnology products.
Pathomechanisms of diseases are described with steps at which neuroprotective therapies are directed. Diseases covered include cerebrovascular disorders, traumatic brain injury, spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy and ischemic optic neuropathy as well as retinal degeneration. Although anesthetics such as propofol are neuroprotective as well, neuroprotection during surgery and anesthesia is discussed with the aim of preventing and treating complications that result in CNS damage.
The report contains a profile of 135 companies that have a neuroprotective product or products along with 96 collaborations. Some of the products in development at academic institutions that do not have a commercial sponsor are also included. Although an up-to-date search of the literature was performed and selected 850 references are included, a considerable amount of information has not been published anywhere else. Clinical trials of various neuroprotective agents are described and failures of trials in stroke and head injury are analyzed with suggestions for improving the selection of drugs and design of trials.The report is supplemented with 63 tables and 10 figures.
Market analysis of currently used productsthat have a neuroprotective effect are analyzed for the year 2008. Some of these products are approved for other indications but are known to have a neuroprotective effect. With the approval of new products and takeover of markets for obsolete symptomatic therapies, the neuroprotection market value will rise by the year 2013 when it will constitute a major and important component of the CNS market. Forecasts are made until 2018. By that time neuroprotection will be an established part of the neurological practice and measures will be available to achieve this effectively.
Customers who bought this item also bought
Neuroprotective Agents: Eighth International Neuroprotection Society Meeting
Drugs of Tomorrow 2001: Neuroprotection - Future Strategies for Success
Neuroprotection in Stroke - Protecting the Brain Sells
Stakeholder Insight: Parkinsons Disease - Evidence of neuroprotection essential to progress treatment dynamics
Cell Therapy - Technologies, Markets and Companies
Gene Therapy - Technologies, Markets and Companies
Alzheimer Disease - New Drugs, Markets and Companies
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Pipeline Insight: Acute Stroke: Commercial Risk Offsets High Unmet Need
Acute Stroke - Considerable Unmet Need is Balanced by Substantial Commercial Risk
Drugs, Devices and Procedures of Tomorrow: Acute Stroke - Chasing the need for speed
Stakeholder Insight: Acute Stroke - TPA Spurs Infrastructure Changes for the Better
|
|
|
|
